KATHLEEN O'BRIEN: Open Payments
NPI 1811173685 · HEBRON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$624 in 34 payments from 14 companies in 2025. Trend: 2023 $757 · 2024 $768 · 2025 $624
Food & beverage: $624
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $205 |
| Novo Nordisk Inc | 5 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $96 |
| Astellas Pharma US Inc | 2 | $41 |
| Amgen Inc. | 2 | $32 |
| Exact Sciences Corporation | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: CAPLYTA, UBRELVY, VRAYLAR, Ozempic, Veozah, OTEZLA, QULIPTA, Cologuard Collection Kit.
Industry payments across KY — which companies pay providers there.
